Dr. Kayvan Zainabadi

Weill Cornell Medicine investigators are developing a new test for TB that circumvents many of the current diagnostic challenges.

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO in Haiti.